title: [Uterine sarcoma associated with tamoxifen use after breast cancer: Review of the pathogenesis].
abstract: Tamoxifen is widely used in the breast cancer treatment. Its side effects on the endometrium are well-known, but more and more worse prognosis uterine sarcoma are described. Based on recent literature review, the cause and effect chain between tamoxifen and uterine sarcoma is argued, which confirms that a risk exists as from 2 years of treatment, a cumulative dose of 15 g, and that malignant mixed mesodermal tumours appear to be the most frequent.
authors.affiliation: Service de gynécologie obstétrique et médecine de la reproduction, CHU de Brest, Brest 29200, France. lionelhomer@yahoo.fr
authors.forename: L
authors.initials: L
authors.lastname: Homer
authors.forename: M
authors.initials: M
authors.lastname: Muller
authors.forename: P-F
authors.initials: PF
authors.lastname: Dupré
authors.forename: B
authors.initials: B
authors.lastname: Lucas
authors.forename: O
authors.initials: O
authors.lastname: Pradier
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D012307:Risk Factors; D012509:Sarcoma / Q000139:chemically induced* / Q000473:pathology; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000473:pathology
chemical_list: D013629:Tamoxifen